Research Article
HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases
Table 3
Average concentrations of serum HE4 and CA125 levels in the different subgroups.
| | Subgroup | HE4 [pmol/L]
mean/range
median/95% confidence intervals
95th percentile | CA 125 [mIU/mL]
mean/range
median/95% confidence intervals
95th percentile | HE4 [pmol/L]
mean/range
median/95% confidence intervals
95th percentile | CA 125 [mIU/mL]
mean/range
median/95% confidence intervals
95th percentile | HE4 [pmol/L]
mean/range
median/95% confidence intervals
95th percentile | CA 125 [mIU/mL]
mean/range
median/95% confidence intervals
95th percentile |
| | | All patients | Premenopausal | Postmenopausal |
| | Nonneoplastic ovarian cysts: | | | | | | |
| | Endometriosis | 49.74/27.5–90.4 | 62.12/8.8–377 | 49.14/33.8–90.4 | 65.71/8.8–377 | 53.93/27.5–73.90 | 36.93/8.8–82.1 | | 46.05/43.7–55.7 | 41.7/30.5–93.8 | 45.4/43.2–55.1 | 43.9/29.9–101.5 | 60.4/−5.3–113.2 | 19.9/−61.2–135.1 | | 73.9 | 131.2 | 66.9 | 131.2 | 73.9 | 82.1 |
| | Teratomas | 47.12/31.9–71.4 | 21.32/17.3–54.35 | 46.89/31.9–71.4 | 22.79/7.8–54.35 | 48.4/47.1–50.5 | 12.93/7.3–16.4 | | 47.45/43–51.2 | 16.45/15.3–27.3 | 47.3/41.9–51.8 | 18.5/15.9–29.6 | 47.6/43.8–52.9 | 15.1/0.7–25.2 | | 63.5 | 53.1 | 71.4 | 54.4 | 50.5 | 16.4 |
| | hemorrhagic corpus luteum cysts | 47.33/28.3–84.7 | 36.5/4.1–111.4 | 46.74/24.8–88.6 | 41.16/6.7–274.8 | 49.9/37.8–61.4 | 16.3/7.5–29 | | 44.3/39.8–54.9 | 15.35/29.9–58.7 | 44.2/37.7–55.8 | 16.1/−3.7–86.2 | 50.5/20.6–79.2 | 12.4/−11.7–44.3 | | 88.6 | 274.8 | 88.6 | 274.8 | 61.4 | 29 |
| | Paraovarian cysts | 54.28/24.8–88.6 | 23.31/6.7–274.8 | 55.15/28.3–84.7 | 29.64/4.10–111.40 | 52.4/40.5–66.1 | 9.73/4.54–16.7 | | 51/47.6–60.9 | 11.95/10.4–36.2 | 48.2/45.7–64.6 | 13.5/11.1–48.2 | 51.7/42.9–61.9 | 7.9/5.6–13.9 | | 78 | 88 | 84.7 | 111.4 | 66.1 | 17.7 |
| | Benign epithelial ovarian tumours: | | | | | | |
| | Serous cystadenomas | 43.79/15–107 | 42.48/8.56–186.72 | 25.63/15–78.2 | 22.54/8.56–55.4 | 61.94/15–107 | 62.42/12.1–186.72 | | 28.51/22.3–65.3 | 26.88/11.2–73.8 | 15/−1.39–52.66 | 16.68/3.3–41.8 | 61.17/27.7–96.2 | 43.9/−4.3–129.2 | | 107 | 186.7 | 78.2 | 55.4 | 107 | 186.7 |
| | Mucinous cystadenomas | 67.21/15–191.1 | 29.12/3.86–64.67 | 40.99/19.2–58.4 | 26.23/11.3–56.40 | 84.69/15–191.1 | 31.04/3.86–64.67 | | 49/41.2–93.3 | 22.2/18.6–39.6 | 42.27/26.7–55.3 | 22/9.9–42.5 | 90.82/43.4–126 | 23.12/14.44–47.64 | | 191.1 | 64.7 | 58.4 | 56.4 | 191.1 | 64.7 |
| | Cystadenofibroma | 39.75/15–62.6 | 17.67/6.35–40 | 39.67/15–62.6 | 11.23/8.86–13.6 | 39.8/15–55.8 | 19.81/6.35–40 | | 44.62/24.8–54.7 | 13.55/8.5–26.9 | 41.41/−19.6–98.9 | 11/−18.9–41.3 | 49/19.4–60.2 | 16.29/7.19–32.44 | | 62.6 | 40 | 62.6 | 13.6 | 45.9 | 49.2 |
| | Other gynecological cancers: | | | | | | |
| | Gonadal tumors | 42.9/23.5–59.8 | 37.1/29.4–49.2 | 59.78/59.78 | 32.8/32.8 | 34.53/23.16–45.9 | 39.3/29.4–49.2 | | 45.9/−2.9–88.9 | 32.8/5.4–48.9 | 59.78/— | 32.8/— | 34.53/−109.9–179 | 39.3/ | | 59.8 | 49.2 | — | — | 45.8 | 49.2 |
| | Vulvar cancer | 90.62/32.9–208.5 | 13.32/8.2–17.6 | 46/32.9–59.1 | 10.9/8.2–13.6 | 99.54/45.65–208.5 | 15.03/11.1–17.6 | | 83.79/60–121.2 | 13.75/6.3–20.4 | 46/−120.5–212.5 | 10.9/−1.2–15.8 | 90.65/65.5–133.6 | 16.4/6.44–23.5 | | 208.5 | 17.6 | 59.1 | 8.2 | 208.5 | 17.6 |
| | Cervical cancer | 56.13/40.4–81.1 | 44.45/12.2–101.5 | 55.57/40.4–81.1 | 42.56/12.2–98.5 | 57/42.7–74.1 | 42.02/13–101.5 | | 53.3/50.6–61.7 | 22.7/20.6–68.1 | 52.6/47.7–63.4 | 17.1/−2.8–88.1 | 57.2/47.6–66.4 | 26.8/−3.78–87.8 | | 78.1 | 101.5 | 81.1 | 98.5 | 74.1 | 101.5 |
| | Ovarian cancers | | | | | | |
| | Serous ovarian cancer | 720.67/15–8160 | 1049.31/9.12–10000 | 352.65/15–1500 | 695.29/25.32–4638.8 | 865.8/18.3–8160 | 1188.92/9.12–10000 | | 414.3/509.4–931.9 | 445/730.4–1368.2 | 119.75/184–521.3 | 382.32/320.4–1070.2 | 639/583.6–1148.1 | 500/768.9–1608.9 | | 1655 | 4638.8 | 1500 | 2096 | 1796.6 | 5109.8 |
| | Mucinous ovarian cancer | 136.97/15–538.66 | 140.56/11.3–600 | 48.65/45.4–51.9 | 26.7/26.4–27 | 166.4/12.58 | 178.52/11.3–600 | | 57.35/−11.2–285.2 | 58.81/−25.2–306.4 | 48.65/7.35–89.9 | 26.7/22.9–30.5 | 76.35/−43–375.8 | 87.16/−51.8–408.8 | | 538.7 | 600 | 51.9 | 27 | 538.7 | 600 |
| | Endometrioid ovarian cancer | 419.07/46.11–1235 | 788.85/41.5–2996.8 | 64.5/64.5 | 500/500 | 454.53/46.107–1235 | 817.74/41.5–2996.8 | | 273/151.7–686.5 | 397/136.4–1441.4 | 64.5/— | 500/— | 289.3/167.8–741.3 | 369.75/88.9–1546.6 | | 1235 | 2996.8 | — | — | 1235 | 29996.8 |
| | Clear cell ovarian cancer | 255.77/49.49–849.9 | 359.1/95.8–991.9 | 75.78/49.49–102.07 | 146.3/95.8–196.8 | 345.76/76.733–849.9 | 465.5/96.4–991.9 | | 119.19/−65.9–577.4 | 193.75/−17.4–735.6 | 75.78/−258.3–409.8 | 146.3/-495.4-787.9 | 228.21/−213.8–905.4 | 386.85/−185.8–1116.8 | | 849.9 | 991.9 | 102.1 | 196.8 | 849.9 | 9991.9 |
|
|
